UK MHRA approves change to the license of Comirnaty Omicron XBB.1.5 30 micrograms/dose
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved a change to the licence of the Comirnaty Omicron XBB.1.5 30 micrograms/dose (single-dose vials) after it was found to meet the UK regulator’s standards of safety, quality and effectiveness.
This approval enables the thawing and re-labelling of the vaccine by a manufacturer outside of the NHS, that has been authorised by the MHRA and confirmed to meet the globally recognised Good Manufacturing Practice standards.
The Comirnaty Covid-19 vaccine needs to be stored at ultra-low temperatures of -80 ºC and then thawed before use. Until now, the thawing and distribution of the Comirnaty Omicron XBB.1.5 30 micrograms/dose vaccine has been centrally managed by the NHS.
The formulation of the vaccine is otherwise the same as that approved by the MHRA in September 2023.
This new authorisation granted by the MHRA is valid in Great Britain only.
Approval has been granted by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for an adapted Novavax Covid-19 vaccine that targets the Omicron XBB 1.5 subvariant, after it was found to meet the UK regulator’s standards of safety, quality and effectiveness.
This vaccine has been approved for use in individuals from 12 years of age.
The vaccine causes the immune system (the body’s natural defences) to produce antibodies and specialised white blood cells that work against the virus, to give protection against Covid-19. None of the ingredients in this vaccine can cause Covid-19.
This new authorisation granted by the MHRA is valid in Great Britain only and was approved via the European Commission (EC) Decision Reliance Route. This is when the marketing authorisation application made by the company references the decision made by the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP). In such cases, the MHRA considers the application together with due consideration of the EC decision, before making an independent decision on the quality, safety, and effectiveness of the vaccine.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!